Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
NCT03981146Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Aug 2019
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in colorectal cancer (CRC), sponsored by University of Birmingham. Started Aug 2019; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03981146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03981146.